Radiomics and predictive imaging are transforming how biotech companies approach drug development and personalized medicine. By extracting quantitative features from medical images that are invisible to the human eye, these technologies offer unprecedented insights into disease characteristics and treatment responses. For biotech firms investing millions in early-phase trials, radiomics provides a powerful tool to enhance success rates and optimize research investments.
Radiomics is a quantitative approach to medical imaging that extracts high-dimensional data from standard medical images using advanced mathematical algorithms. Unlike traditional imaging analysis that relies on visual interpretation, radiomics uncovers hidden patterns and features that can predict clinical outcomes with remarkable accuracy.
"Radiomics involves the extraction of high-dimensional data from medical images, enabling a quantitative analysis of tumor characteristics beyond traditional qualitative assessments,"
For biotech companies, the implications are profound. With 9 out of 10 pivotal clinical trials in oncology failing, according to Radiomics.bio, radiomics offers a way to identify promising candidates earlier and optimize trial design for better outcomes.
The radiomics process follows a structured workflow that transforms standard medical images into valuable biomarkers:
This systematic approach enables biotech researchers to develop robust imaging biomarkers that can inform critical decisions throughout the drug development pipeline.
Also Read: Clinical Trial Imaging Market: Size, Growth Analysis
Early-phase clinical trials are critical junctures where promising therapies either advance or fail. Radiomics can significantly improve these trials in several ways:
One of the most valuable applications of radiomics in biotech is patient stratification. By identifying imaging biomarkers that correlate with treatment response, companies can:
Traditional response criteria like RECIST 1.1 have limitations, particularly for novel therapies with unique mechanisms of action. Radiomics offers more sensitive and specific measures of treatment response:
This capability allows biotech companies to make informed go/no-go decisions earlier in the development process, potentially saving millions in research costs.
Also Read: Understanding Good Clinical Practice (GCP) in Imaging
A significant advantage of radiomics is its ability to analyze the relationship between lesion-specific responses and overall patient outcomes.
"A radiomic analysis can also be used to explore the correlation between lesion response (local) and patient response (global), so that phase III trials can be designed to recruit the “right” patients, those that are phenotypically more likely to respond and therefore maximize the compound value." according to experts at Radiomics.bio.
This insight helps biotech companies develop more accurate endpoints for pivotal trials, increasing the likelihood of regulatory approval.
Traditional imaging biomarkers typically focus on simple measurements like tumor size or volume. Radiomics represents a paradigm shift by:
| Traditional Imaging | Radiomics Approach |
|---|---|
| Measures a few predefined features | Extracts hundreds or thousands of features |
| Relies on visual interpretation | Uses computational algorithms |
| Limited ability to capture heterogeneity | Comprehensively characterizes tissue properties |
| Primarily descriptive | Highly predictive |
This comprehensive approach provides biotech researchers with a much richer dataset for developing predictive models and making data-driven decisions.
Also Read: FDA Guidelines for Imaging Trials: Ensuring Quality and Compliance
The combination of radiomics and artificial intelligence, particularly deep learning, is creating even more powerful tools for biotech companies:
While traditional radiomics relies on predefined features, deep learning can:
"Deep Learning approaches utilize neural networks to learn features directly from imaging data, aiming to predict clinical outcomes, treatment responses, and tumor characteristics,"
For biotech companies developing complex therapies like cell and gene treatments, these advanced analytical capabilities can provide crucial insights into mechanism of action and patient selection.
Despite its promise, implementing radiomics in biotech research faces several challenges:
Variability in imaging protocols, scanner types, and reconstruction methods can affect the reproducibility of radiomic features. To address this:
Developing reliable radiomic models requires:
Biotech companies can overcome these challenges through collaborations with academic centers, imaging CROs, and data sharing initiatives.
As a relatively new technology, radiomics faces regulatory hurdles:
Early engagement with regulatory agencies can help address these issues and establish a path for incorporating radiomics into pivotal trials.
While oncology has been the primary focus of radiomics research, its applications are expanding to other therapeutic areas relevant to biotech:
This expansion opens new opportunities for biotech companies working across multiple therapeutic areas to leverage radiomics for more efficient drug development.
A recent study demonstrated how radiomics could identify responders to immunotherapy in non-small cell lung cancer patients. By analyzing pre-treatment CT scans, researchers developed a radiomic signature that predicted treatment response with significant accuracy—outperforming conventional clinical predictors.
For the biotech company sponsoring the trial, this meant:
This example illustrates how radiomics can create value throughout the drug development and commercialization process.
As competition in the biotech sector intensifies, companies that effectively leverage radiomics and predictive imaging will gain significant advantages:
By investing in radiomics capabilities now, forward-thinking biotech companies can position themselves at the forefront of the precision medicine revolution, ultimately delivering greater value to patients and shareholders alike.
Radiomics focuses on extracting quantitative features from medical images, while radiogenomics specifically links these imaging features with genomic data. As defined by researchers, "Radiomics is defined as a high-throughput feature-extraction method that unlocks microscale quantitative data hidden within standard-of-care medical imaging. Radiogenomics is defined as the linkage between imaging and genomics information."
Traditional image analysis typically relies on visual interpretation by radiologists and simple measurements like tumor size. Radiomics extracts hundreds or thousands of quantitative features that may not be visible to the human eye, providing a much richer characterization of tissue properties.
Radiomics can be applied to virtually any medical imaging modality, including CT, MRI, PET, ultrasound, and digital pathology. Each modality offers different types of features and information that can be extracted and analyzed.
Small biotech companies can leverage radiomics through partnerships with academic institutions, specialized imaging CROs, or by using commercial radiomics platforms. Cloud-based solutions are also making advanced image analysis more accessible without requiring significant infrastructure investments.
A growing body of research demonstrates the value of radiomics in predicting treatment response, patient outcomes, and disease characteristics across multiple therapeutic areas. While still evolving, the field has shown promising results in improving patient stratification and early response assessment in clinical trials.
Reviewed by: Mathias Engström on May 16, 2025